Stelara and Medicare Part B: Is It Covered?

Stelara is one of those medications that can make people feel betterand make insurance paperwork feel worse.
If you’re on Medicare (or helping someone who is), the question usually isn’t “Does Stelara work?”
It’s “Which part of Medicare is going to pay for it… and why is the answer a maze?”

Here’s the good news: once you understand one simple ideahow Stelara is giventhe Medicare
coverage picture gets a lot clearer. The not-as-good news: that clarity may arrive about three phone calls
later than you wanted. Let’s save you those calls.

What Stelara is (and why Medicare treats it like a special case)

Stelara is the brand name for ustekinumab, a biologic medicine used for several inflammatory
conditions, including plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis.
“Biologic” is Medicare-speak for “not your typical pill,” and often “priced like it’s made of moon rocks.”

The part that matters most for coverage is how it’s administered:
many people use Stelara as a subcutaneous injection (a shot under the skin), typically on a
schedule like every 8 to 12 weeks depending on the condition and dosing plan.
For Crohn’s disease and ulcerative colitis, there’s often an IV induction dose (a one-time infusion)
followed by ongoing self-injections.

Medicare Part B vs. Part D: two buckets, one expensive splash

Think of Medicare drug coverage like two different checkout lanes:

• Part B is the “clinic lane.” It usually covers drugs that are
  administered by a healthcare professional in a doctor’s office, outpatient clinic, or infusion center.
• Part D is the “pharmacy lane.” It generally covers
  self-administered outpatient prescription drugs, including many specialty medications you inject at home.

Stelara lives right on the border between these lanesbecause it can be infused (IV) in certain situations
and injected (often at home) in many others.

So… is Stelara covered under Medicare Part B?

Most of the time: no (because it’s usually self-administered)

For the subcutaneous injection form of Stelara, Medicare usually treats it as a
self-administered drug. And in Medicare-world, “self-administered” often means:
“Part B, please exit the building.”

Why? Medicare contractors follow guidance that generally excludes drugs from Part B when they’re
usually self-administered by patients. Even if a clinician is willing to give the injection,
Medicare may still consider the drug “self-administered” in the big-picture, population-level sense.
Translation: Medicare doesn’t want Part B turned into a backdoor pharmacy benefit.

The common exception: the IV induction dose (Crohn’s disease & ulcerative colitis)

Here’s where Part B may step in: if you receive Stelara as an intravenous infusion in an outpatient
settingespecially the one-time induction dose used for Crohn’s disease or ulcerative colitis
that administration can fit the typical Part B pattern: provider-administered, medically supervised, billed as
an outpatient service.

After that induction infusion, the ongoing maintenance is commonly a subcutaneous injectionoften done at home
which pushes coverage back toward Part D.

“What if my doctor gives me the shot in-office?”

This is where people get whiplash. Historically, there were situations where a physician-administered Stelara
injection might have been billed under Part B. More recently, Medicare contractor policies have moved toward
excluding Stelara injections from Part B coverage under rules meant to keep “usually self-administered” drugs
out of Part Beven when administered by a clinician.

The practical takeaway: don’t assume that “doctor gives the shot” automatically equals “Part B pays.”
Ask the billing team how they will bill it, and which benefit (B or D) they expect to apply.
It’s not paranoiait’s paperwork prevention.

When Stelara lands in Part D (the most common path)

If your Stelara is a self-injectable medication you receive through a specialty pharmacy,
it’s typically handled under Medicare Part D (or the drug coverage portion of a Medicare Advantage plan).
That includes:

• Most Stelara use for plaque psoriasis and psoriatic arthritis
• Maintenance dosing for Crohn’s disease and ulcerative colitis after an IV induction dose

Under Part D, Stelara is usually placed on a specialty tier. That often comes with
prior authorization, and sometimes step therapy (depending on the plan and diagnosis).
Plans differso your neighbor’s coverage story might be fascinating, but it’s not a guarantee of yours.

Medicare Advantage: the same rules, with extra “fine print seasoning”

Medicare Advantage (Part C) plans must cover what Original Medicare covers, but they manage care through
networks, utilization rules, and plan-specific formularies. In real life, that means:

• Your IV induction may need to be done at an in-network infusion center, with plan approval.
• Your self-injectable Stelara will run through the plan’s Part D-style pharmacy benefit,
  often with a preferred specialty pharmacy.
• Prior authorization may be required for both medical and pharmacy benefitssometimes with different forms,
  because the universe enjoys irony.

What you might pay: Part B math vs. Part D math (choose your adventure)

If Stelara is covered under Part B

Under Original Medicare, Part B generally involves a deductible and then coinsurance
(often 20% of the Medicare-approved amount) for covered outpatient services.
If you have a Medigap (Medicare Supplement) plan, that coinsurance may be partially or fully covered
depending on your specific policy.

Part B billing is typically “buy and bill” (the provider purchases the drug and bills Medicare),
which can simplify logistics for patientsbut doesn’t automatically make out-of-pocket costs disappear.
The exact amount depends on coverage, supplemental insurance, and how the service is billed.

If Stelara is covered under Part D

Part D costs vary by plan: premiums, deductibles, and cost-sharing can differ widely.
Specialty drugs may involve coinsurance rather than a flat copay, which can feel like your wallet
is being asked to “participate in the treatment plan.”

The big affordability headline in recent years is the addition of an annual out-of-pocket cap
for Part D. If you reach the cap for covered Part D drugs in a given year, you generally won’t pay additional
copays or coinsurance for covered drugs for the rest of that year (details depend on program rules and what counts).
For many people on high-cost specialty medications, this can be a meaningful guardrail.

A quick example (because abstract math is rude)

Scenario A: Crohn’s disease
You get a one-time Stelara IV induction at an outpatient infusion center. That may be billed under
Part B. Eight weeks later, you switch to subcutaneous maintenance injectionsoften
shipped to you by a specialty pharmacytypically under Part D.
Same medication family, different Medicare bucket, different cost-sharing rules.

Scenario B: Plaque psoriasis
You use subcutaneous injections on a maintenance schedule. That’s typically Part D coverage,
with plan-specific rules like prior authorization and a specialty tier.

How to confirm coverage (before your mailbox delivers a jump scare)

1. Start with the route: Are you getting an IV infusion or a self-injection?
   This single detail predicts Part B vs. Part D more than anything else.
2. Ask the provider how they bill: “Will you bill Medicare Part B for the drug,
   or will it be filled through a Part D specialty pharmacy?” If they hesitate, that’s your cue
   to ask for the billing specialist.
3. Check your Part D formulary: Look up Stelara (ustekinumab) and see if it’s covered,
   which tier it’s on, and what restrictions apply (prior authorization, quantity limits, step therapy).
4. Confirm the site of care: For IV infusions, coverage can depend on whether you’re in a
   hospital outpatient department vs. an independent infusion center. Billing rules and patient responsibility
   can differ.
5. Get the approval in writing: Prior authorization decisions, coverage determinations,
   and specialty pharmacy approvals should be documented. “They said it would be fine” is not a bill-payment strategy.

If coverage is denied: smart next moves (instead of rage-refreshing your portal)

Denials happen for reasons that range from legitimate (missing documentation) to maddening (formulary rules).
Your options often include:

• Prior authorization appeal: Ask your prescriber to submit clinical notes showing diagnosis,
  previous therapies tried, and why Stelara (or ustekinumab) is appropriate.
• Formulary exception request: If Stelara isn’t covered or is placed with unfavorable rules,
  you may be able to request an exceptionespecially if alternatives are not tolerated or ineffective.
• Plan shopping: During Medicare Open Enrollment, reviewing Part D or MA-PD options can be
  worthwhile if a medication is ongoing and expensive.
• Consider biosimilars (with your clinician): New ustekinumab biosimilars may be preferred on some formularies,
  potentially improving access or cost. “Preferred” doesn’t always mean “cheaper for you,” but it often changes coverage paths.

The biosimilar era: “ustekinumab” isn’t always spelled S-t-e-l-a-r-a anymore

The U.S. market has seen a growing list of ustekinumab biosimilars (biosimilar versions of Stelara).
Some have been approved with “interchangeable” status for certain presentations, which can influence how payers
and pharmacies handle substitutions (subject to state laws and plan rules).

What that means for Medicare beneficiaries in plain English:

• Your plan may cover a biosimilar preferred product and require special justification for brand Stelara.
• The name on the box might change, but it’s still ustekinumab-based therapyyour clinician will decide what’s appropriate.
• Formularies can change year to year, especially when new competitors enter the market.

Bottom line

If you came for a one-sentence answer, here it is:
Stelara is usually covered under Medicare Part D, and only sometimes under Part Bmost notably when it’s given as an IV infusion in an outpatient setting.

The easiest way to predict the coverage bucket is to ask: “Am I injecting this myself?”
If yes, Part D is the usual destination. If it’s infused by a provider, Part B may apply.
And if you’re getting an injection in a clinic, verifybecause policy details can turn that “maybe” into a “nope.”

The winning strategy is boring but effective: confirm the route, confirm the billing benefit, confirm the approval,
and keep a paper trail. Your future self (and your blood pressure) will thank you.

Real-world experiences: what people learn the hard way (so you don’t have to)

1) The “I thought it was Part B forever” surprise.
“Diane” started Stelara for ulcerative colitis. Her first dose was an IV infusion at an outpatient center,
and everything felt very Part-B-ish: check in, get the infusion, go home, repeat the story to friends who
are tired of hearing about parking validation. The bill was manageable because she had a supplement plan.
Then, eight weeks later, her doctor said, “Greatnow you’ll do injections at home.” Diane assumed it would
be billed the same way. Nope. The maintenance injections were routed to a specialty pharmacy under her Part D plan.
Different deductible, different coinsurance, different phone menu. Her lesson: always ask,
“Is this next dose billed the same way as the first one?”

2) The specialty pharmacy relay race.
“Marco” (psoriatic arthritis) had coverage on paper, but getting the medication in hand took coordination:
the plan required prior authorization, the specialty pharmacy needed the prescription, and the clinic needed
to confirm dosing and shipping timing. The first shipment got delayed because someone’s fax machine apparently
lived in 1997. What finally worked was treating the process like a project: Marco kept a single-page log of
dates, names, and reference numbers. When someone said, “We never received that,” he could respond with
the verbal equivalent of a receipt. The moral: politeness plus documentation is a superpower.

3) The in-office injection that still didn’t count as Part B.
“Evelyn” hated needles and asked her doctor’s office to administer the Stelara injection.
She figured, “If a professional does it, Part B will cover it.” The office was willingMedicare was not.
The claim ran into the “usually self-administered” wall. The staff explained that coverage depends on how Medicare
classifies the drug in general, not how brave Evelyn feels that day. In the end, her Part D plan covered it,
and the office helped coordinate training so she could self-inject confidently. Her takeaway:
the setting matters, but classification rules can matter more.

4) The “my costs got capped, but I still needed cash flow” reality.
“Howard” was on a high-cost specialty regimen under Part D and learned about the annual out-of-pocket cap.
That helpedeventually. The tricky part was timing: even with a yearly cap, costs can be front-loaded early in the year,
depending on how a plan structures deductibles and coinsurance. Howard’s best move was asking his plan about
options to spread costs more evenly (and coordinating refill timing so he didn’t create a “January financial earthquake”).
The point isn’t that everything becomes cheap; it’s that planning makes it less chaotic.

5) The biosimilar switch that wasn’t scary (after the first five minutes).
“Nina” got a formulary update notice that read like a robot trying to be ominous: her plan would “prefer” a biosimilar
ustekinumab product instead of brand Stelara. Her initial reaction was, “Great. My medication is getting rebranded.”
After a call with her clinician and pharmacist, she learned the biosimilar had the same therapeutic target and had been
evaluated under FDA standards for biosimilarity. The switch was mostly an administrative event: new prior authorization,
new specialty pharmacy routing, and a new name to remember. Her advice: don’t panicask whether the plan is requiring
a switch, what the expected patient cost will be, and how the prescription process changes.

Across these stories, the pattern is consistent: the medication is clinical, but the coverage is operational.
You’re not “bad at Medicare” if it feels confusingMedicare is just very committed to making you confirm things twice.
The best approach is to treat Stelara coverage like travel: confirm your ticket (Part B vs Part D), confirm the gate
(infusion center vs specialty pharmacy), and keep your confirmation number (prior auth) somewhere you can actually find it.
Preferably not in a junk drawer with a coupon for a store that closed in 2009.